Giving hope to those affected
by secondary breast cancer

Research. Support. Education.

Make 2nds Count Joins Drug Consultation Process for Elacestrant

27th March 2024 by Sarah Thomas

Instagram Post 13

In a first for the charity, we are working with the National Institute for Health and Care Excellence (NICE) as a stakeholder in the drug consultation process for a new treatment for secondary breast cancer called Elacestrant.

Elacestrant is currently approved to treat people in the EU and USA living with oestrogen receptor-positive (HR+) HER2-negative (HER2-) secondary breast cancer with an ESR1 mutation, who experience disease progression after at least one line of hormone therapy. It is an oral medicine, and shown to double progression-free survival in clinical trials.

As a stakeholder in this consultation process, Make 2nds Count will be able to submit evidence, nominate patient experts, comment on consultation documents produced during the drug appraisal, and appeal against the final draft recommendation.

And that's where we need your help! To make your voice heard about Elacestrant, please share your views by 12 April: 

Elacestrant offers hope to those who are at risk of developing a resistance to hormone therapies, which is often caused by the ESR1 mutation.

In recent times we have been heartbroken to see proven life-extending treatments for secondary breast cancer not being recommended for use on the NHS, despite being approved in the EU and USA, and therefore only being made available to those in the UK who can pay privately. 

We believe that the key to unlocking free access to urgently needed new treatments for secondary breast cancer in the UK is to amplify the voice of our patient community, so we are standing alongside charities such as Breast Cancer Now and METUP UK, in taking part in the drug consultation process and ensuring your voices will be heard.

Once a new medicine is licensed for use in the UK, the next decision is whether it will be made available as part of our free healthcare system. 

NICE evaluates new medicines and health technologies for NHS use in England, analysing research evidence and value for money. In the rest of the UK, these decisions are made by:

  • Scotland - Scottish Medicines Consortium (SMC)
  • Wales - All Wales Medicines Strategy Group (AWMSG) 
  • Northern Ireland - Department of Health, Social Services and Public Safety (DHSSPS) 

Please take part in this important process and share your views with us by 12 April: